Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer

Bronchial Cancer Clinical Trial

Official title:

Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03328559
• Other study ID #: CTC
• Status: Completed
• Phase: N/A
• Start date: March 7, 2016
• Est. completion date: August 20, 2021

Study information

• Verified date: August 2021
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The pronostic value of Circulating Tumoral Cells(CTC) 's dosage by the method ISET® (tumoral cell isolation by size) in patients with bronchial cancer was previously demonstrated.

However, no kinetic study was ever realized to study the value of the CTC as predictive indicator of answer to the therapy. This project plans to study patients in an early stage and patients at advance stage locally moved forward or metastatic of the disease by evaluation of the presence and the number of CTC before every cure. This collaborative and original study should allow to refine the diagnoses of answer and to plan the possible relapses what would allow a premature institution of the treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: August 20, 2021
• Est. primary completion date: November 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with non-small cell lung cancer

• accepting participation

Exclusion Criteria:

• refusing participation

Related Conditions & MeSH terms

• Bronchial Cancer
• Carcinoma, Bronchogenic

Intervention

Diagnostic Test:
• ISET® - Isolation by Size of Tumor cells
early stage bronchial cancer patient will have a blood collection
• ISET® - Isolation by Size of Tumor cells
advanced stage bronchial cancer patient will have a blood collection

Locations

Country	Name	City	State
France	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	numeration of CTC (circulant tumoral cell)		Day 1